Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/SS18_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/SS18_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/SS18_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/SS18_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00163589 | Prostate | BPH | dendrite development | 71/3107 | 243/18723 | 5.73e-07 | 1.14e-05 | 71 |
GO:001077010 | Prostate | BPH | positive regulation of cell morphogenesis involved in differentiation | 31/3107 | 79/18723 | 1.27e-06 | 2.22e-05 | 31 |
GO:00507695 | Prostate | BPH | positive regulation of neurogenesis | 63/3107 | 225/18723 | 1.11e-05 | 1.51e-04 | 63 |
GO:00507678 | Prostate | BPH | regulation of neurogenesis | 92/3107 | 364/18723 | 1.36e-05 | 1.78e-04 | 92 |
GO:00488136 | Prostate | BPH | dendrite morphogenesis | 45/3107 | 146/18723 | 1.46e-05 | 1.88e-04 | 45 |
GO:00519623 | Prostate | BPH | positive regulation of nervous system development | 67/3107 | 272/18723 | 4.15e-04 | 3.01e-03 | 67 |
GO:00519604 | Prostate | BPH | regulation of nervous system development | 100/3107 | 443/18723 | 6.02e-04 | 4.16e-03 | 100 |
GO:0048814 | Prostate | BPH | regulation of dendrite morphogenesis | 20/3107 | 67/18723 | 4.93e-03 | 2.33e-02 | 20 |
GO:002260418 | Prostate | Tumor | regulation of cell morphogenesis | 102/3246 | 309/18723 | 1.25e-11 | 9.49e-10 | 102 |
GO:001076917 | Prostate | Tumor | regulation of cell morphogenesis involved in differentiation | 41/3246 | 96/18723 | 5.10e-09 | 2.05e-07 | 41 |
GO:001072013 | Prostate | Tumor | positive regulation of cell development | 88/3246 | 298/18723 | 1.22e-07 | 3.17e-06 | 88 |
GO:001077015 | Prostate | Tumor | positive regulation of cell morphogenesis involved in differentiation | 32/3246 | 79/18723 | 1.01e-06 | 1.95e-05 | 32 |
GO:001635814 | Prostate | Tumor | dendrite development | 72/3246 | 243/18723 | 1.44e-06 | 2.59e-05 | 72 |
GO:001097514 | Prostate | Tumor | regulation of neuron projection development | 115/3246 | 445/18723 | 3.34e-06 | 5.44e-05 | 115 |
GO:003134614 | Prostate | Tumor | positive regulation of cell projection organization | 94/3246 | 353/18723 | 6.96e-06 | 1.05e-04 | 94 |
GO:005076911 | Prostate | Tumor | positive regulation of neurogenesis | 64/3246 | 225/18723 | 2.26e-05 | 2.88e-04 | 64 |
GO:004881312 | Prostate | Tumor | dendrite morphogenesis | 45/3246 | 146/18723 | 4.45e-05 | 5.02e-04 | 45 |
GO:005076711 | Prostate | Tumor | regulation of neurogenesis | 93/3246 | 364/18723 | 4.45e-05 | 5.02e-04 | 93 |
GO:005196211 | Prostate | Tumor | positive regulation of nervous system development | 69/3246 | 272/18723 | 4.99e-04 | 3.67e-03 | 69 |
GO:005196011 | Prostate | Tumor | regulation of nervous system development | 102/3246 | 443/18723 | 1.20e-03 | 7.60e-03 | 102 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SS18 | SNV | Missense_Mutation | | c.199N>A | p.Ser67Thr | p.S67T | Q15532 | protein_coding | deleterious(0.01) | probably_damaging(0.99) | TCGA-AC-A23C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | chemo | CR |
SS18 | SNV | Missense_Mutation | | c.635C>G | p.Ser212Cys | p.S212C | Q15532 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.922) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
SS18 | SNV | Missense_Mutation | | c.236N>A | p.Pro79His | p.P79H | Q15532 | protein_coding | deleterious(0.02) | probably_damaging(0.969) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SS18 | SNV | Missense_Mutation | | c.637C>G | p.Gln213Glu | p.Q213E | Q15532 | protein_coding | deleterious_low_confidence(0.05) | possibly_damaging(0.449) | TCGA-C8-A26W-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
SS18 | SNV | Missense_Mutation | rs377058145 | c.295C>T | p.Pro99Ser | p.P99S | Q15532 | protein_coding | tolerated_low_confidence(0.86) | benign(0.063) | TCGA-C8-A8HQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SS18 | insertion | Frame_Shift_Ins | novel | c.1253_1254insAAAATCT | p.Ter419LysfsTer37 | p.*419Kfs*37 | Q15532 | protein_coding | | | TCGA-A7-A26I-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD |
SS18 | SNV | Missense_Mutation | novel | c.373N>A | p.Gly125Ser | p.G125S | Q15532 | protein_coding | tolerated_low_confidence(0.06) | benign(0.389) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SS18 | SNV | Missense_Mutation | rs753910503 | c.476N>T | p.Ser159Phe | p.S159F | Q15532 | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-AA-3930-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | capecitabine | PD |
SS18 | SNV | Missense_Mutation | | c.450N>T | p.Met150Ile | p.M150I | Q15532 | protein_coding | tolerated_low_confidence(0.18) | benign(0.391) | TCGA-AA-3994-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | capecitabine | CR |
SS18 | insertion | In_Frame_Ins | novel | c.974_975insTGATAA | p.Gly325_Asn326insAspLys | p.G325_N326insDK | Q15532 | protein_coding | | | TCGA-AM-5820-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |